HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap EURRegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 26.3 | -11.1 | -10.4 | 6.8 | -7.6 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 16/05/2024 | EUR 118.97 | |
Day Change | -0.15% | |
Morningstar Category™ | Other Equity | |
ISIN | LU1540962211 | |
Fund Size (Mil) 16/05/2024 | USD 24.11 | |
Share Class Size (Mil) 16/05/2024 | EUR 0.16 | |
Max Initial Charge | 3.00% | |
Ongoing Charge 19/02/2024 | 2.27% |
Investment Objective: HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap EUR |
The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Ivo Staijen 31/12/2011 | ||
Inception Date 24/01/2018 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap EUR | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Zealand Pharma A/S | Healthcare | 5.90 |
Vertex Pharmaceuticals Inc | Healthcare | 5.84 |
Regeneron Pharmaceuticals Inc | Healthcare | 5.76 |
Amgen Inc | Healthcare | 5.67 |
Blueprint Medicines Corp | Healthcare | 4.73 |
Increase Decrease New since last portfolio | ||
HBM UCITS (Lux) Funds - HBM Global Biotechnology Fund P Cap EUR |